Kangya Pharmaceutical

About Kangya Pharmaceutical

Ningxia Kangya Pharmaceutical Co., Ltd. is a high-tech enterprise focused on the research, development, production, and sale of chemical drug preparations and active pharmaceutical ingredients (APIs). The company's predecessor, Ningxia Kangya Pharmaceutical Factory, was established in September 1992. In 1996, it merged with Northwest Pharmaceutical Co., Ltd. to become Ningxia Kangya Pharmaceutical Co., Ltd. and was officially established on September 28, 1996. It was converted into a joint-stock company in April 2017 and was listed on the National Equities Exchange and Quotations (NEEQ) in November 2017. The current chairman and legal representative is He Zhongtong.

Headquartered in Yinchuan, the company operates two production sites, the Jinfeng campus for R&D and solid dosage form production, and the Suyin campus for APIs and liquid preparations. Kangya Pharmaceutical specializes in treatments for cardiovascular diseases, senile chronic diseases, and eye diseases. Its product portfolio includes tablets, granules, capsules, eye drops, and APIs, with 51 approved product specifications. Key products are Indapamide Sustained-Release tablets, which hold the second-largest market share in their national segment, and Calcium Dobesilate capsules, which passed the national generic drug consistency evaluation in 2019. The company's business model is driven by R&D, with R&D expenses accounting for approximately 14-15% of total revenue in recent years. Revenue is generated from the sale of its pharmaceutical products through a mature sales network of over 10,000 pharmaceutical companies and medical institutions across China.

Kangya has received numerous accolades, including being named a "National Torch Plan Key High-tech Enterprise" in 2013. Its R&D efforts are supported by various government-recognized platforms, including a National and Local Joint Engineering Laboratory. The company has undertaken national and regional key R&D projects and holds numerous patents. In July 2025, six of its projects, including Lomefloxacin Hydrochloride Eye Drops and Amlodipine Besylate Tablets, passed the consistency evaluation for generic drugs, and the company received a government subsidy of four million RMB.